FDA OKs riociguat for pulmonary hypertension

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

The FDA has approved riociguat for adults with two forms of pulmonary hypertension under its priority review program.

Riociguat (Adempas), a soluble guanylate cyclase stimulator, is indicated for patients with chronic thromboembolic pulmonary hypertension after surgery or patients who cannot undergo surgery to improve their ability to exercise; and in patients with pulmonary arterial hypertension to improve their ability to exercise and to delay clinical worsening of their condition.

The FDA’s Cardiovascular and Renal Drugs Advisory Committee panel voted unanimously for its approval in August.

Riociguat should not be prescribed to pregnant women because it can harm the developing fetus, according to its Boxed Warning. The drug is available to women only through a restricted program, the Adempas Risk Evaluation and Mitigation Strategy Program. It also is contraindicated for co-administration with nitrates or nitric oxide donors in any form and concomitant administration with phosphodiesterase inhibitors.

Wayne, N.J.-based Bayer HealthCare Pharmaceuticals markets the drug.

Candace Stuart, Contributor

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."